Related Experiment Video

Updated: Sep 26, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice

Oliver Kisker1, Shinya Onizuka, Christian M Becker

  • 1Division of Surgical Research, Children's Hospital, Boston, MA 02115, USA.

Neoplasia (New York, N.Y.)
|March 28, 2003
PubMed

Insights

A modified vitamin D binding protein (DBP-maf) shows potent anti-cancer effects. This deglycosylated protein inhibits tumor growth, reduces blood vessel formation, and promotes cancer cell death in preclinical models.

Area of Science:

  • Biochemistry
  • Oncology
  • Immunology

Background:

  • Vitamin D binding protein (DBP) is a key player in vitamin D transport.
  • Pancreatic cancer remains a significant health challenge with limited treatment options.

Purpose of the Study:

  • To investigate the anti-cancer properties of a selectively deglycosylated form of DBP (DBP-maf).
  • To evaluate DBP-maf's efficacy as an antiangiogenic and antiproliferative agent against pancreatic cancer.

Main Methods:

  • Isolation of DBP-maf from a human pancreatic cancer cell line.
  • In vitro assessment of antiproliferative effects on endothelial cells.
  • In vivo efficacy studies in immunocompromised mice bearing human pancreatic tumors.
  • Histological analysis of tumor tissues, including microvessel density, macrophage infiltration, and apoptosis.

Main Results:

  • DBP-maf demonstrated potent antiangiogenic activity in the chorioallantoic membrane assay.
  • Daily administration of DBP-maf significantly inhibited pancreatic tumor growth (T/C=0.09) and induced tumor regression at higher doses.
  • Histological analysis revealed reduced microvessel density, increased macrophage infiltration, and elevated apoptosis in DBP-maf treated tumors.

Conclusions:

  • DBP-maf exhibits significant antiangiogenic and direct anti-tumor effects.
  • DBP-maf acts by inhibiting endothelial cell proliferation and stimulating macrophage-mediated tumor cell attack.
  • DBP-maf represents a promising therapeutic candidate for pancreatic cancer treatment.

More Related Videos

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair09:34

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair

Published on: September 7, 2017

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...